| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.3 | 4e-16 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.27 | 9e-14 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.25 | 9e-12 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-11 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.23 | 4e-09 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.3 | 1e-08 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-08 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.17 | 6e-08 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.18 | 9e-08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |